Marforio Tainah Dorina, Carboni Andrea, Calvaresi Matteo
Dipartimento di Chimica "Giacomo Ciamician", Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy.
Cancers (Basel). 2023 Oct 11;15(20):4944. doi: 10.3390/cancers15204944.
Carboranes have emerged as one of the most promising boron agents in boron neutron capture therapy (BNCT). In this context, in vivo studies are particularly relevant, since they provide qualitative and quantitative information about the biodistribution of these molecules, which is of the utmost importance to determine the efficacy of BNCT, defining their localization and (bio)accumulation, as well as their pharmacokinetics and pharmacodynamics. First, we gathered a detailed list of the carboranes used for in vivo studies, considering the synthesis of carborane derivatives or the use of delivery system such as liposomes, micelles and nanoparticles. Then, the formulation employed and the cancer model used in each of these studies were identified. Finally, we examined the analytical aspects concerning carborane detection, identifying the main methodologies applied in the literature for ex vivo and in vivo analysis. The present work aims to identify the current strengths and weakness of the use of carboranes in BNCT, establishing the bottlenecks and the best strategies for future applications.
碳硼烷已成为硼中子俘获疗法(BNCT)中最有前景的硼剂之一。在此背景下,体内研究尤为重要,因为它们能提供有关这些分子生物分布的定性和定量信息,这对于确定BNCT的疗效、明确其定位和(生物)蓄积以及其药代动力学和药效学至关重要。首先,我们收集了用于体内研究的碳硼烷的详细清单,考虑了碳硼烷衍生物的合成或脂质体、胶束和纳米颗粒等递送系统的使用。然后,确定了每项研究中采用的制剂和使用的癌症模型。最后,我们研究了有关碳硼烷检测的分析方面,确定了文献中用于离体和体内分析的主要方法。本工作旨在确定碳硼烷在BNCT应用中的当前优势和劣势,找出瓶颈以及未来应用的最佳策略。